MiR-22 as a metabolic silencer and liver tumor suppressor  

作　　者：Lijun Wang Yu-Shiuan Wang Eko Mugiyanto Wei-Chiao Chang Yu-Jui Yvonne Wan 

机构地区：[1]Department of Pathology and Laboratory Medicine,University of California Davis,Sacramento,CA [2]The College of Life Science,Yangtze University,Jingzhou,Hubei [3]PhD Program in Clinical Drug Development of Chinese Herbal Medicine,College of Pharmacy,Taipei Medical University,Taipei [4]Department of Clinical Pharmacy,School of Pharmacy,Taipei Medical University,Taipei

出　　处：《Liver Research》2020年第2期74-80,共7页肝脏研究（英文）

基　　金：This study was supported by grants funded by the National In-stitutes of Health U01CA179582 and R01CA222490;UC Davis Comprehensive Cancer Center seed grant,and UC Davis Global Affairs seed grant.

摘　　要：With obesity rate consistently increasing,a strong relationship between obesity and fatty liver disease has been discovered.More than 90%of bariatric surgery patients also have non-alcoholic fatty liver diseases(NAFLDs).NAFLD and non-alcoholic steatohepatitis(NASH),which are the hepatic manifesta-tions of metabolic syndrome,can lead to liver carcinogenesis.Unfortunately,there is no effective medicine that can be used to treat NASH or liver cancer.Thus,it is critically important to understand the mechanism underlying the development of these diseases.Extensive evidence suggests that microRNA 22(miR-22)can be a diagnostic marker for liver diseases as well as a treatment target.This review paper focuses on the roles of miR-22 in metabolism,steatosis,and liver carcinogenesis.Literature search is limited based on the publications included in the PubMed database in the recent 10 years.

关 键 词：MicroRNA-22(miR-22) Cancer Liver METABOLISM STEATOSIS Non-alcoholic steatohepatitis HEPATITIS 

分 类 号：R735.7[医药卫生—肿瘤]